ClinicalTrials.gg

Program

pyronaridine

Also written as “Pyronaridine”, “Pyronaridine Tetraphosphate” and “Pyronaridine 540 mg”.

Its studies are mostly in Malaria, Falciparum · Leukemia, Myeloid, Acute, led by 3 companies.

Furthest: phase 2, since Jan 9, 20234 company-led studies, 1 open or runningNext primary completion: Apr 5, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany20 open or runningphase 2since Jan 9, 2023Jan 9, 2023none ahead
Armaceutica10 open or runningphase 2since Oct 7, 2021Oct 7, 2021none ahead
Merck11 open or runningphase 1since Oct 30, 2026Oct 30, 2026Apr 5, 2027phase 1 · NCT07919028

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2021First study: phase 2 study in Leukemia, Myeloid, AcuteNew to ArmaceuticaArmaceutica · NCT05291390 · 200 enrolled · Senegal
  2. Jan 9, 2023Merck KGaA, Darmstadt, Germany's first study: phase 2 study in Acute malariaNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT05689047 · 38 enrolled · Burkina Faso, Gabon, Mozambique and more
  3. Jul 25, 2023Phase 2 study in Malaria, FalciparumMerck KGaA, Darmstadt, Germany · NCT05974267 · 192 enrolled · Burkina Faso, Kenya, The Gambia and more
  4. Oct 30, 2026Merck's first study: phase 1 study in HealthyNew to MerckMerck · NCT07919028 · 24 planned

Ahead

  1. Apr 5, 2027Primary completion: phase 1 study in HealthyMerck · NCT07919028

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07919028Healthy1Not yet recruitingMerckApr 5, 202724
NCT05974267Malaria, Falciparum · Burkina Faso, Kenya, The Gambia and more2CompletedMerck KGaA, Darmstadt, GermanyDec 29, 2024192
NCT05689047Acute malaria · Burkina Faso, Gabon, Mozambique and more2CompletedMerck KGaA, Darmstadt, GermanyMay 28, 202438
NCT05291390Leukemia, Myeloid, Acute · Senegal2SuspendedArmaceuticaFeb 2030200

How it is read

Names in the registry

  • “Pyronaridine”, 2 entries
  • “Pyronaridine Tetraphosphate”, 1 entry
  • “Pyronaridine 540 mg”, 1 entry
  • “Pyronaridine 720 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.